EP1416272A4 - Recepteur pael, cellules et animal exprimant ce recepteur pael et methode de selection d'un remede contre la maladie de parkinson - Google Patents
Recepteur pael, cellules et animal exprimant ce recepteur pael et methode de selection d'un remede contre la maladie de parkinsonInfo
- Publication number
- EP1416272A4 EP1416272A4 EP02738872A EP02738872A EP1416272A4 EP 1416272 A4 EP1416272 A4 EP 1416272A4 EP 02738872 A EP02738872 A EP 02738872A EP 02738872 A EP02738872 A EP 02738872A EP 1416272 A4 EP1416272 A4 EP 1416272A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pael receptor
- parkinson
- disease
- cells
- pael
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000018737 Parkinson disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001197185 | 2001-06-28 | ||
JP2001197185A JP2003018992A (ja) | 2001-06-28 | 2001-06-28 | Pael受容体、Pael受容体発現細胞および動物、ならびにパーキンソン病治療薬のスクリーニング法 |
PCT/JP2002/006587 WO2003003010A1 (fr) | 2001-06-28 | 2002-06-28 | Recepteur pael, cellules et animal exprimant ce recepteur pael et methode de selection d'un remede contre la maladie de parkinson |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1416272A1 EP1416272A1 (fr) | 2004-05-06 |
EP1416272A4 true EP1416272A4 (fr) | 2005-02-09 |
Family
ID=19034834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02738872A Withdrawn EP1416272A4 (fr) | 2001-06-28 | 2002-06-28 | Recepteur pael, cellules et animal exprimant ce recepteur pael et methode de selection d'un remede contre la maladie de parkinson |
Country Status (4)
Country | Link |
---|---|
US (1) | US20060051835A1 (fr) |
EP (1) | EP1416272A4 (fr) |
JP (1) | JP2003018992A (fr) |
WO (1) | WO2003003010A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004013637A1 (fr) * | 2002-08-01 | 2004-02-12 | Bayer Healthcare Ag | Moyens de diagnostic et moyens therapeutiques utiles pour les maladies associees au recepteur 37 couple a la proteine g (gpr37) |
WO2005103681A1 (fr) * | 2004-04-24 | 2005-11-03 | Bayer Healthcare Ag | Moyens diagnostiques et therapeutiques pour les maladies associees a la proteine 1 analogue au recepteur d'endotheline de type b (etbr-lp-1) |
US8017348B1 (en) | 2005-12-12 | 2011-09-13 | Elan Pharma International Limited | Assay for Parkinson's Disease therapeutics |
WO2007089334A2 (fr) * | 2005-12-12 | 2007-08-09 | Elan Pharmaceuticals, Inc. | Analyse visant à identifier des traitements de la maladie de parkinson et préparations de protéine parkine enzymatiquement active utilisées dans celle-ci |
EP2158487A1 (fr) * | 2007-05-21 | 2010-03-03 | Elan Pharma International Limited | Substrat et dosage de la parkine |
JP5903044B2 (ja) * | 2010-06-25 | 2016-04-13 | 日本臓器製薬株式会社 | 被検物質の判定又は評価方法 |
WO2012099279A1 (fr) | 2011-01-21 | 2012-07-26 | 独立行政法人理化学研究所 | Construction d'acide nucléique destinée à exprimer un indicateur de stress oxydatif, et son utilisation |
GB2497948A (en) | 2011-12-22 | 2013-07-03 | Thermo Fisher Scient Bremen | Collision cell for tandem mass spectrometry |
JP7203367B2 (ja) * | 2017-12-14 | 2023-01-16 | 公益財団法人実験動物中央研究所 | 哺乳動物細胞用遺伝子導入ベクター |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750370A (en) * | 1995-06-06 | 1998-05-12 | Human Genome Sciences, Inc. | Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011946A1 (fr) * | 1994-10-17 | 1996-04-25 | Human Genome Sciences, Inc. | Recepteur pour la bombesine et l'endotheline d'origine humaine |
US6555339B1 (en) * | 1997-04-14 | 2003-04-29 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human protein-coupled receptors |
-
2001
- 2001-06-28 JP JP2001197185A patent/JP2003018992A/ja active Pending
-
2002
- 2002-06-28 US US10/482,028 patent/US20060051835A1/en not_active Abandoned
- 2002-06-28 EP EP02738872A patent/EP1416272A4/fr not_active Withdrawn
- 2002-06-28 WO PCT/JP2002/006587 patent/WO2003003010A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750370A (en) * | 1995-06-06 | 1998-05-12 | Human Genome Sciences, Inc. | Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor |
Also Published As
Publication number | Publication date |
---|---|
US20060051835A1 (en) | 2006-03-09 |
WO2003003010A1 (fr) | 2003-01-09 |
JP2003018992A (ja) | 2003-01-21 |
EP1416272A1 (fr) | 2004-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005097140A3 (fr) | Antagonistes selectifs des recepteurs a2a de l'adenosine | |
GB9909966D0 (en) | Analysis of fundus images | |
IL164839A0 (en) | Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas | |
AU2001264950A1 (en) | Methods of screening for parkinson's disease | |
EP1416272A4 (fr) | Recepteur pael, cellules et animal exprimant ce recepteur pael et methode de selection d'un remede contre la maladie de parkinson | |
IL159067A0 (en) | METHODS FOR PREPARATION AND USE OF 1alpha,24 (S) -DIHYDROXYVITAMIN D2 | |
EP1036844A4 (fr) | Technique d'examen, reactif pour examen et medicament relatif a des affections provoquees par des modifications survenues dans le gene lkb1 | |
AU2001273661A1 (en) | Methods of screening for alzheimer's disease | |
EP1404326A4 (fr) | Methode de traitement de la maladie de parkinson | |
AU2002339228A1 (en) | System for intracellular process monitoring and in vivo drug screening | |
AU2002352054A1 (en) | "in vitro" diagnostic method for diseases affecting human or animal tissues | |
AUPP870999A0 (en) | Method of treatment of equine disease | |
IL172690A0 (en) | Methods for the diagnosis and prognosis of alzheimer's disease | |
WO2001079560A3 (fr) | Test de reaction a des medicaments contre des maladies respiratoires | |
AU2002313304A1 (en) | Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinsons disease | |
AU2003253298A8 (en) | System and method of processing electromyographic signals for the diagnosis of parkinson's disease | |
EP1207201A4 (fr) | Proteine recepteur couplee a une proteine g et adn correspondant | |
AU2003251962A8 (en) | Screening for alzheimer's disease | |
EP1438431A4 (fr) | Methodes permettant de diagnostiquer et de traiter les maladies cardiaques | |
AU2003237172A1 (en) | Cell cultures from animal models of alzheimer's disease for screening and testing drug efficacy | |
AU2003218601A1 (en) | Phox2b polymorphisms as hirschsprung's disease diagnostic markers and methods based thereon | |
EP1329516A4 (fr) | Technique de criblage de substance physiologiquement active | |
EP1118621A4 (fr) | Nouvelle proteine receptrice couplee a la proteine g, et son adn | |
EP1408808A4 (fr) | Methodes de diagnostic et de traitement des maladies cardiaques | |
AU2002341044A1 (en) | Methods for detecting parkinson's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040128 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041230 |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20050317 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20071004 |